Q1 2026 13F · SEC CIK 2103725
AIHC Capital Management Ltd
Hedge fundFiled 2026-05-08 for Q1 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $119.7M
- Reported positions
- 5
- Holdings vs S&P 500, 3 yrs
- —
- Average holding period
- 2 qtrs
AIHC Capital Management Ltd is a hedge fund that reported 5 positions worth $119.7M in its Q1 2026 13F, filed 2026-05-08. Its largest holdings were Revolution Medicines Inc (RVMD, 67.4%), Oric Pharmaceuticals Inc (ORIC, 26.0%), Novabridge Biosciences (IMAB, 4.7%).
AIHC Capital Management Ltd holdings all 5 positions.
Weights are shares of the filer's total reported 13F value, compared with Q4 2025. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| RVMDRevolution Medicines Inc | 67.4% | -7.9% | $80.6M |
| ORICOric Pharmaceuticals Inc | 26.0% | — | $31.2M |
| IMABNovabridge Biosciences | 4.7% | +446.6% | $5.6M |
| COGTCogent Biosciences Inc | 1.7% | -48.6% | $2.0M |
| KRROKorro Bio Inc | 0.3% | +0.0% | $343K |
What AIHC Capital Management Ltd bought and sold in Q1 2026, against Q4 2025.
New positions
- ORIC Oric Pharmaceuticals Inc26.0% of 13F
Added to
- IMAB Novabridge Biosciences+446.6% shares
Reduced
- COGT Cogent Biosciences Inc-48.6% shares
- RVMD Revolution Medicines Inc-7.9% shares
Sold out
- PTGX Protagonist Therapeutics Incwas 15.5%
- AVBP Arrivent Biopharma Incwas 12.2%
Share counts compared with the Q4 2025 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- —
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q1 2026 | $119.7M | 5 |
| Q4 2025 | $106.7M | 6 |
Questions about AIHC Capital Management Ltd's portfolio
What stocks does AIHC Capital Management Ltd own?
AIHC Capital Management Ltd's latest 13F, for Q1 2026 and filed May 8, 2026, lists 5 positions worth $119.7M. The largest are Revolution Medicines Inc (RVMD) at 67.4%, Oric Pharmaceuticals Inc (ORIC) at 26.0%, Novabridge Biosciences (IMAB) at 4.7%, Cogent Biosciences Inc (COGT) at 1.7% and Korro Bio Inc (KRRO) at 0.3%.
What did AIHC Capital Management Ltd buy last quarter?
In Q1 2026, AIHC Capital Management Ltd added a new position in Oric Pharmaceuticals Inc (ORIC) and Novabridge Biosciences (IMAB) (+446.6% shares), compared with its Q4 2025 filing.
What did AIHC Capital Management Ltd sell last quarter?
In Q1 2026, AIHC Capital Management Ltd sold all of Protagonist Therapeutics Inc (PTGX), sold all of Arrivent Biopharma Inc (AVBP), Cogent Biosciences Inc (COGT) (-48.6% shares) and Revolution Medicines Inc (RVMD) (-7.9% shares), compared with its Q4 2025 filing.
When is AIHC Capital Management Ltd's next 13F filing due?
13F filings are due 45 days after each quarter ends. AIHC Capital Management Ltd's filing for the quarter ending Jun 30, 2026 was due by Aug 14, 2026; this page updates once it is processed.